Nine pharmaceutical companies competing to develop the first new crown vaccine have promised that any new crown vaccine they produce will be developed and tested in accordance with “high ethical standards and sound scientific principles”. The statement appears to be an effort by the pharmaceutical industry to allay public concerns that the vaccine approval process may be affected by political or other interests rather than safety. “We believe that this commitment will help to ensure public confidence in the rigorous scientific and regulatory procedures that will evaluate and possibly eventually be approved for the covid-19 vaccine,” said the statement, signed by each company’s CEO The Wall Street Journal reported on Friday for the first time the commitment plans of these companies. Among them, the statement promised that the companies would “always make the safety and well-being of vaccinated individuals our top priority.”. < / P > < p > the statement was issued a week after the initial vaccine distribution plan of the Centers for Disease Control and Prevention (CDC) surfaced. These documents require local and state governments to begin developing preliminary plans for vaccine distribution, noting that “limited covid-19 vaccine doses may be available by early November 2020” or by the end of October 2020. < / P > < p > since then, experts have expressed their view that this schedule is “extremely unlikely” and stressed the importance of preparing complex distribution systems in advance. But this point, just before the US presidential election, has exacerbated existing concerns that the race to find vaccines is becoming politicized. According to a survey by stat news, even before the CDC documents were published, 78% of Americans were worried that the approval process for new vaccines was driven more by politics than science. < / P > < p > the four companies that have signed the letter of commitment Pfizer, biontech, Moderna and AstraZeneca have vaccines in large phase III clinical trials. Pfizer and biontech are working together to develop a candidate drug that has reached this level. This phase involves tens of thousands of volunteers to prove that the candidate vaccine is safe and effective. < / P > < p > if data from one of the trials shows promise, developers can choose to send the information to the food and Drug Administration (FDA), which has the authority to approve vaccines in the United States. The approval process is very strict and, usually, can take several years. But the FDA said it may be willing to grant emergency use authorization for the vaccine, which will take much shorter time. < / P > < p > the recent emergency authorization for covid-19 treatment has proved to be highly controversial. Less than two weeks after the FDA authorized the use of convalescent plasma, a team from the National Institutes of Health said there was not enough data to recommend plasma as a treatment for patients with covid-19. Earlier this year, the FDA issued an emergency authorization for hydroxychloroquine, then revoked the order, finding it unlikely to be effective and had serious side effects. < / P > < p > FDA director Stephen Hahn said in June that in addition to proving that the vaccine is safe and that to obtain FDA approval, pharmaceutical companies will have to prove that their vaccines are 50% more effective than placebo. < / P > < p > in addition to promising to put the well-being of vaccinators first and not requiring FDA approval or authorization of vaccines in the absence of strong data from phase III trials, these companies have also made other proposals Two commitments. < / P > < p > according to the New York Times vaccine tracking report, about 37 vaccines are in different stages of human trials, and many others are still being tested or developed in animals. IPhone 12 whole family barrel model exposed: it’s a tribute to iPhone 4